The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points between 1 month and more than 2 years after transplantation. A high frequency of donorderived LB-reactive CTLp was detectable 2-6 months after BMT in all children and persisted for at least up to 18 months in the eight patients in haematological remission, while it rapidly declined in the only patient who relapsed. Generation of LB-reactive T cell clones obtained from some of these patients demonstrates that various T lymphocyte subsets, either HLA class Irestricted/TCR-dependent or HLA-unrestricted, contribute to this phenomenon. The in vitro GVL effect here described seems to be at least partially separated from GVHR, since no correlation was observed between the emergence of LB-reactive CTLp and the development and/or severity of GVHD. Development of LBreactive CTL in the patients was independent of the frequency of these cells in the donor. These data suggest that donor-derived CTL activity specifically directed towards leukaemic blasts may develop in patients given allogeneic BMT and contribute to the maintenance of a state of haematological remission. Keywords: CTL; bone marrow transplantation; leukaemia relapse; graft-versus-host disease; graft-versusleukaemia Allogeneic bone marrow transplantation (BMT) is being used with increased frequency to cure patients with acute and chronic leukaemia.
development of a donor cell-mediated immune effect, referred to as graft-versus-leukaemia (GVL). The immunemediated antileukaemic effect of allogeneic BMT has been extensively studied in animal models, [2] [3] [4] whereas biological data in humans are less conclusive and further information on the nature of this phenomenon is needed. Clinical evidence indicates that mature T cells of donor origin transferred with the bone marrow (BM) are involved in the development of both the graft-versus-host reaction (GVHR) and the GVL effect. 5, 6 In fact, T cell depletion procedures of donor BM result in a reduced incidence and severity of GVHD, as well as in an increased risk of leukaemia relapse, and this suggests a strict relationship between GVHR and GVL. 7, 8 CTL specifically directed towards widely distributed or tissue-restricted minor histocompatibility (mH) Ag or leukaemia-specific antigens have been claimed to play a major role in the GVL phenomenon observed in patients receiving HLA-identical BMT, whereas disparity for HLA antigens is considered to be the most important factor in the generation of an immune-mediated anti-leukaemia effect in recipients of mismatched transplant. 9, 10 Biological support for these hypotheses is provided by the observation that CTL directed towards HLA-identical or disparate allogeneic leukaemic blasts (LB) can be detected in the PBMC of healthy donors in vitro. [11] [12] [13] [14] [15] [16] Even though GVL effect is believed to be closely related to GVHR, mounting evidence obtained in both mouse models [17] [18] [19] [20] and humans 16, [21] [22] [23] indicates that the GVL effect may, at least partially, be separate from GVHR. Since in a previous report we demonstrated that CTL clones directed against autologous LB could be obtained from PBMC and BM of leukaemic children by in vitro lymphocyte stimulation with autologous tumor cells and rIL-2, 24 we decided to study the in vitro GVL effect in a group of children given allogeneic BMT from an HLA-identical sibling or an unrelated volunteer. For this purpose, we established a limiting dilution assay (LDA) in order to measure the frequency of CTL precursors (CTLp) directed against either recipient LB or non-leukaemic pre-transplant recipient cells, which were used as a control to test the specificity of CTL. Using this approach, we found that CTLp reactive towards recipient LB were undetectable or low in donors' PBMC, while they reached remarkably high values in patients after allogeneic BMT and persisted for several months in recipients remaining in haematological remission.
Patients and methods

Patients
Nine children affected by acute myelogenous leukaemia (AML, six cases) or by acute lymphoblastic leukaemia (ALL, three cases) were included in the study. Six children (CT, NM, MD, PD, IS, ER) were given allogeneic BMT from an HLA-identical sibling, while three children (QP, MS, NP) received BMT from a matched unrelated donor (MUD). All patients received an unmanipulated transplant. Details of patients' characteristics, conditioning regimen, GVHD prophylaxis and clinical outcome are reported in Table 1 . The four patients developing acute GVHD and the two patients experiencing both acute and chronic GVHD received steroid treatment (prednisone 2 mg/kg/day). Details of the duration of steroid therapy for each patient are reported in Table 1 .
All six children receiving BMT from an HLA-identical sibling have remained in complete haematological remission after BMT, with an observation time ranging from 18 to 35 months. One patient who received BMT from a MUD relapsed 8 months after transplant, while the two remaining patients are in complete haematological remission with an observation time of 1 year. In all cases chromosomal analysis of PBMC and BM together with the study of genetic polymorphism of a variable number of tandemly repeated short DNA sequences demonstrated a complete donor chimerism.
Cell preparation and cell line establishment
Heparinized BM aspirates containing Ͼ90% LB were obtained from patients at the time of diagnosis and BM remission cells (BMRC) were collected after demonstration of complete haematological remission. PBMC were obtained from donors at the time of BM harvest and from patients at different time points after BMT. LB, BMRC and Table 1 Clinical characteristics of patients and donors PBMC were isolated by Ficoll-Hypaque density gradient, cryopreserved in FCS (Gibco, Paisley, UK) supplemented with 10% DMSO and stored in liquid nitrogen. Before BMT, T lymphoblastoid cell lines (T-LCL) were established for each patient by stimulating PBMC with PHA (Gibco; M-form 1:100) and serial passages in RPMI 1640 (Gibco) supplemented with 2 mm l-glutamine, 50 g/ml gentamicine, 10% FCS and rIL-2 (Hoffmann-La Roche, Nutley NJ, USA; 100 U/ml). PHA blasts (PHA-B) were obtained by stimulating pre-transplant recipient PBMC with PHA, at the concentration employed for T-LCL, for 3 days. EBV-induced B-LCL (EBV-LCL) were obtained from pre-transplant recipient PBL as previously described. 25 
Patients Diagnosis Conditioning Type of A-GVHD Duration of C-GVHD Duration of Duration of
Outcome regimen donor A-GVHD C-GVHD corticosteroid therapy CT AML Bu/Cy/L-PAM Sib. II sg +33 → +80 limited +90 → +120 +33 → +120 A&W, +35 months NM AML Bu/Cy/L-PAM Sib. 0 NA absent NA none A&W, +33 months MD ALL TBI/TT/Cy Sib. I +9 → +17 absent NA +9 → +19 A&W, +28 months +26 → +70 +26 → +80 PD ALL TBI/TT/Cy Sib. I +10 → +19 absent NA +11 → +23 A&W, +19 months +26 → +50 +30 → +58 IS ALL TBI/TT/Cy Sib. II s +8 → +19 absent NA +8 → +20 A&W, +18 months +26 → +71 +28 → +82 ER AML TBI/L-PAM
Limiting dilution assay
The medium used was RPMI 1640 supplemented with 2 mm l-glutamine, 50 g/ml gentamicine, 1% non-essential amino acids, 1 mm sodium pyruvate (Gibco), 5% pooled human serum (HS-RPMI) and 100 U/ml rIL-2. PBMC of either donors or recipients after BMT were employed as responder cells, while autologous LB of transplanted patients were used as stimulators. Decreasing numbers of PBMC (8 × 10 
Cytotoxicity assay
On day 10, cultures were assayed for cytolytic activity against 51 Cr-labeled targets, which included recipient LB, T-LCL, BMRC, PHA-B and EBV-LCL. Briefly, 2-3 × 10 6 target cells were labeled with 200-300 Ci 51 Cr (Dupont, Boston, MA, USA) for 2 h and washed three times. After removal of 100 l of supernatant from all the assay wells, 5 × 10 3 target cells were added to each well. Alternatively, wells were accurately resuspended and 100 l of each well transferred for split experiments. The plates were incubated for 4 h at 37°C and then centrifuged at 200 g for 10 min. Finally, 100 l of supernatant were collected from each well and counted for 1 min in a gamma-counter. To provide necessary controls, spontaneous and total 51 Cr release from target cells were also determined. Spontaneous release from all types of target cell was consistently less than 20%.
Calculation of leukaemia-reactive CTLp frequency
Assay wells were defined as positive when 51 Cr release exceeded the average + 3 s.d. of control wells. The frequency of responding cells was determined by maximum likelihood estimation using a statistical program and the variance by the use of 95% confidence limits. 26 mAbs for phenotyping and blocking experiments mAb used in this study included:
, anti-HLA class I (W6/32) (Dakopatts, Glostrup, Denmark) and TR66, an anti-CD3 mAb, which was generously provided by Professor A Lanzavecchia.
27 Phenotypic analysis of cell populations was performed by means of direct or indirect immunofluorescence on a FACScan flow cytometer (Becton Dickinson). Blocking of cytolytic activity with TR66 anti-CD3 and anti-HLA class I (W6/32) mAb was performed as follows: (1) target cells were previously incubated with anti-HLA class I mAb (25 g/ml) for 30 min at 4°C; (2) effector cells were previously incubated with anti-CD3 mAb (1 g/ml) for 30 min at 4°C. Subsequently, the same concentration of each mAb was added to microcultures in the 4 h standard cytotoxicity assay.
Generation of leukaemia-reactive cytotoxic T cell clones
LB-reactive effector cells of patients MD, IS and ER were recovered from pooled positive wells obtained from 10-day LDA, and seeded in HS-RPMI into Terasaki trays at 0.3 cells/well in the presence of rIL-2 (200 U/ml), PHA (Gibco; M-form 1:100), irradiated (30 Gy) autologous LB (2 × 10 5 /ml) and allogeneic feeder cells (5 × 10 5 /ml). After 12-14 days of culture, all growing wells were harvested and expanded by cultivation in U-shaped 96-well plates with 10 6 /ml irradiated allogeneic feeder cells in HS-RPMI containing 200 U/ml rIL-2 and PHA. Conditions for the maintenance of T cell clones (TCC) have been described elsewhere. 28 The clones thus obtained were screened for their capacity to lyse recipient LB in a 51 Cr release assay. Thereafter, LB-reactive TCC were further characterized for their surface phenotype and specificity.
Results
Leukaemia-reactive CTLp frequency analysis
BMT-induced in vitro GVL effect was investigated by measuring the frequency of CTLp directed to recipient LB in the PBMC of the patients at different time points after BMT. LB-reactive CTLp were also determined in the donors at the time of BM harvest.
As shown in Table 2 , the frequency of LB-reactive CTLp was undetectable (Ͻ1/200 000) or low in the PBMC of five of the six donors employed for related BMT and in all unrelated volunteers.
In the first two patients receiving BMT from siblings (CT and NM), LB-directed CTLp frequencies were evaluated starting from 2 months after transplant (Table 3) . In both patients a high frequency of cytolytic cells was documented repeatedly from 2 to 18 months after BMT, and only when tested at 35 and 33 months, respectively, was the frequency of LB-reactive CTLp found to be undetectable. We then decided to advance to 1 month after BMT the evaluation of LB-reactive CTLp in the other patients. Results demonstrated that cytolytic cells were undetectable 1 month after transplant in all remaining children. In patient MD, CTLp frequency was found to be very low 1.5 months after BMT and increased thereafter to reach and maintain very high values. A detectable CTLp frequency was already found 1.5 months after BMT in patient PD, and fluctuations of frequency levels were observed in the three subsequent determinations. Further determinations of LB-reactive CTLp in this patient were not performed as no more aliquots of LB were available. In patient IS a measurable CTLp frequency was observed at only 3 months and the highest values were observed between 4 and 12 months after BMT. In patient ER, LB-reactive CTLp were undetectable until 4 months, reached high values at 6 and 12 months after BMT and decreased thereafter.
Results concerning patients given BMT from MUD are reported in Table 4 . Patient QP reached high values of LB directed CTLp frequency 4 months after transplant; then, these values rapidly declined in the following weeks. This patient relapsed 8 months after BMT and died of leukaemia progression. In the remaining two patients, sizeable values of CTLp were observed about 4 months after BMT; since then, the frequencies progressively increased to reach high levels 6-8 months after transplantation.
Notably, LB-reactive CTLp emerged and persisted also in children with acute or chronic GVHD, who had been The fraction of negative wells was plotted on a logarithmic scale against the number of responder cells/well. Frequency is also reported. Results are expressed as frequency and 95% confidence limits (in brackets). ND = not done; NA = not applicable.
treated with steroids for this complication (see also Table 1 for further details). The frequency of CTLp able to lyse recipient pre-transplant T-LCL was determined in all donors and patients given a related BMT by employing split experiments. Results showed that T-LCL-reactive CTLp were undetectable (frequency Ͻ1/200 000) in all related BM donors (data not shown) and in four out of six patients receiving allogeneic BMT from HLA-identical siblings (Table 5 ). In Table 5 Patients' CTLp frequency measured in LDA against recipients' LB and various sources of non-leukaemic pre-transplant recipient cells patients PD and IS, T-LCL reactive CTLp could be detected at 4 months after BMT (1/14 833 and 1/83 692, respectively). In patient PD, the T-LCL reactive frequency was slightly higher than that obtained against autologous LB (1/22 343). Nevertheless, analysis of split single positive wells enabled us to demonstrate that in less than 20% of positive wells were both targets lysed. In addition to pretransplant recipient T-LCL, other sources of non-leukaemic recipient cells were available and used as target cells in some experiments. In particular, in the group of related BMT recipients, EBV-LCL were tested in patients CT and MD, BMRC were available in patients CT and IS, while PHA blasts were used in patients CT and MD. Results reported in Table 5 confirmed that the CTLp frequencies against different pre-transplant recipient non-leukaemic cells were undetectable or lower that those found against LB. In Table 5 data regarding representative experiments performed 4 or 6 months after BMT are reported. In children receiving BMT from MUD, sizeable or high values of CTLp directed towards BMRC were found during the observation time. Nevertheless, in these patients also, analysis of split experiments demonstrated that in only 20-30% of wells were both LB and BMRC lysed. Notably, patient QP maintained a high frequency of CTLp directed against BMRC 6 and 8 months after transplant when, by contrast, the LB-directed CTLp frequency declined (Table 4) . + . In all cultures analyzed CD4 + lymphocytes were less than 10%.
Surface phenotype of effector cells obtained from LDA
Surface phenotype and cytolytic activity of LB-reactive T cell clones
Effector subsets mainly involved in the development of cytotoxic activity against recipient LB were further characterized by cloning in limiting dilution pooled positive wells derived from LDA cultures. In particular, LDA of patients MD, IS and ER, were cloned when LB-directed CTLp frequency was 1/4373, 1/12 510 and 1/5170, respectively. The growing clones were expanded, screened for their capacity to lyse recipient LB and T-LCL in a cytotoxicity assay, and evaluated for the presence of ␣␤ or ␥␦ TCR. TCC able to mediate cytotoxic activity against recipient LB but not T-LCL, were defined as LB-reactive and those including 100% of ␣␤ + or ␥␦ + cells were chosen for further investigations.
Different types of LB-reactive TCC could be defined on the basis of the surface phenotype. Ten of 12 TCC from patient IS could be expanded sufficiently to be tested against both pre-transplant autologous BMRC, allogeneic primary LB and allogeneic BMRC obtained from two other patients affected by ALL and AML, respectively (Figure 1) tested in blocking experiments with anti-CD3 and anti-HLA class I mAb (Table 6 ). The killing capacity of the ␥␦ + /DN TCC and of the ␣␤ + /DN TCC was not affected by addition of the two mAb. Addition of these mAbs strongly reduced cytolytic activity of two out of three ␣␤ + /CD8 + TCC, while anti-CD3 mAb, but not anti-HLA class I mAb was able to inhibit cytotoxicity in the remaining ␣␤ + /CD8 + clone. No further investigation on HLA restriction or TCR involvement was performed due to the short-term viability displayed in vitro by the LB-reactive TCC. Expression of some costimulatory/accessory molecules was evaluated on leukaemic autologous or allogeneic target cells, showing that all LB were CD80 negative, but expressed CD54 (ICAM-1), CD58 (LFA-3) and HLA-class I Ag; CD86 molecule was not expressed in any patients but one (IS), in whom there was a 'dim' positivity in more than 90% of cells.
Discussion
This study demonstrates that CTLp reactive towards recipient LB develop in children given allogeneic BMT and persist for at least 18 months in patients in haematological remission. Notably, in the only child who experienced leukaemia recurrence 8 months after an unrelated volunteer BMT, LB-reactive CTLp developed early after transplant, but, subsequently, the frequency of these cells declined a few weeks before haematological relapse. The GVL effect that we observed in vitro seems not to be strictly correlated with GVHR given that the emergence of a high frequency of LB-reactive CTLp was not related to the occurrence and severity of clinical GVHD.
Surface marker evaluation of LB-reactive cell lines and TCC showed that several types of CTL clones can contribute to anti-leukaemic activity in vitro, including CD3 + /TCR␣␤ + /CD8 + , CD3 + /TCR␥␦ + /CD8 + lymphocytes and CD3
+ /CD4/CD8DN cells expressing either ␥␦ or ␣␤ TCR. Analysis of target specificity of the different TCC subtypes demonstrates either a specific killing of recipient LB or non-specific pattern of cytotoxicity, which can also be directed towards HLA-disparate ALL and AML LB. In keeping with our data, clones able to display a broad specificity toward different tumour cells have been previously Table 6 Effect of the addition of anti-CD3 and anti-HLA class I mAb on the cytolytic activity displayed by TCC, obtained from patient ER, against autologous pretransplant LB Results are expressed as percent of specific lysis at an E:T ratio of 1:1. Surface phenotype of each TCC is also reported.
described in patients with solid tumours. 29 Even though we cannot exclude that NK cells were at least partially involved in the in vitro anti-leukaemia activity observed, immune phenotype of LB-reactive cell lines and the specificity for autologous LB of the majority of these lines seem to favour a major role of T lymphocytes. Moreover, NK activity has its greatest expression during the early period after BMT, when the in vitro anti-leukaemia response of our children was undetectable or low.
It is well known that the CD80-CD86 co-stimulation pathway plays a critical role in HLA-restricted, TCRmediated activation of T cells. [30] [31] [32] In particular, it has been recently demonstrated that the lack of expression of the B7 family, and/or other molecules involved in immune responsiveness, on the surface of LB may induce T lymphocyte unresponsiveness or anergy, while, by contrast, the presence of CD80 or CD86 on tumor cells as well as the use of leukaemia dendritic cells as stimulators may induce a vigorous leukaemia-reactive cytotoxic activity. [33] [34] [35] It is noteworthy that the LB used in this study as stimulator and target cells did not express CD80, and a weak expression of CD86 molecules was only observed on LB surface of patient IS. Moreover, LB-reactive TCC generated in vitro displayed a CD28-negative or CD28 dim phenotype, this observation being in agreement with our previously published data on the identification and characterization of LBreactive CD3 + /CD8 + /CD28 − CTL clones expressing TCR␣␤, in peripheral blood and BM of children with acute leukaemia in haematological remission after chemotherapy. 24 Since the inefficient delivery of crucial co-stimulatory signals may facilitate the development of alternative pathways of target cell recognition, 36 it is conceivable to hypothesize that the in vitro GVL effect observed in our patients was mediated by both HLA-restricted CTL directed towards mH-Ag 11-14 and other CTL subsets using a TCR-CD3-independent pathway. The isolation of LBreactive TCR␥␦ + CTL after BMT confirms previous reports in patients with solid tumours or acute leukaemia on the potential role of these cells in anti-cancer immune surveillance. [37] [38] [39] It has recently been reported that leukaemia-reactive CTL clones can be generated in vitro before BMT from PBMC of HLA-identical BM donors of leukaemia patients. 13, 14 This observation could account for the measurable values of recipient LB-reactive CTLp observed in PBMC of the donors of patients CT and PD. However, a high frequency of recipient LB-reactive CTLp was also reached by those patients whose donors did not show a detectable frequency of these precursors in peripheral blood, thus indicating that the emergence of LB-reactive CTLp is not strictly related to the potential immune response of the donor against recipient LB.
Given that in patients receiving BMT from compatible siblings, undetectable or low frequencies of CTLp reactive against non-leukaemic recipient cells were obtained from LB-stimulated LDA and that LB-reactive TCC, unable to lyse non-malignant pre-transplant recipient cells could be isolated from some of these patients, our results raise questions on the antigenic stimuli capable of eliciting expansion of this specific LB-reactive CTL response. It is tempting to speculate that the presence of recipient LB escaping the preparative regimen may have induced the development of a high frequency of leukaemia-reactive CTLp. In particular, to explain the selective reactivity of the CTL response towards LB, it can be hypothesized that leukaemia-specific peptide antigens could be recognized by T lymphocytes able to mount a cytotoxic response. In this regard, it is interesting to note that two children had AML M 3 , a leukaemia subtype characterized by the tumor-specific PML/RAR␣ fusion protein containing an antigenic site, previously demonstrated to be recognizable by CD4
+ T lymphocyte clones with cytotoxic activity. 40 Molecular monitoring of PML/RAR␣ translocation performed through PCR amplification in our patients after BMT showed an early transient positivity of the fusion protein (data not shown). Alternative mechanisms accounting for the specific LB recognition and consistent with our results could involve a differential expression of mHAg within the haematopoietic system. 10 In particular, polymorphic peptides that may normally be expressed by myeloid cells, but not by lymphatic cells, may act in patients with AML as leukaemia-associated antigens which are recognized by CTL unable to lyse T-or B-LCL. Furthermore, CTL response could be directed towards either the expression of stress proteins or 'superantigens' on neoplastic cells 41 or the overexpression of normal non-polymorphic differentiation proteins which may break tolerance and elicit an immune response. In support of this latter hypothesis, some examples of immunogenic peptides derived from proteins expressed in both myeloid and lymphoid ontogeny have recently been reported. [41] [42] [43] [44] In conclusion, our data demonstrate that the expansion of various CTL populations with anti-leukaemia activity is a common feature in children given allogeneic BMT. Evaluation of a larger number of patients is needed to verify whether the presence of a high frequency of LB-reactive CTLp after BMT can predict the persistence of a state of remission as the outcome of these patients seems to suggest. A long-term follow-up of transplanted patients experiencing leukaemia recurrence would also be important to investigate the possible role of mechanisms of immune escape from GVL effect through clonal evolution of LB after BMT. 34 
